Eli Lilly lifts 2026 revenue guidance to $87 billion after Zepbound and Mounjaro drive quarterly beat
LLY is in focus after Eli Lilly easily topped quarterly earnings estimates and raised its full-year 2026 revenue outlook, with Zepbound and Mounjaro sales cited as the demand catalyst. The